» Articles » PMID: 10583448

Renal Hemodynamic Changes During Smoking: Effects of Adrenoreceptor Blockade

Overview
Publisher Wiley
Specialty General Medicine
Date 1999 Dec 3
PMID 10583448
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cigarette smoking accelerates progression of renal failure in diabetic and nondiabetic renal disease. Renal hemodynamics during smoking are characterised by a reversible decrease in glomerular filtration rate (GFR) and filtration fraction (FF) accompanied by increased renovascular resistance (RVR), systemic blood pressure, heart rate and plasma catecholamine concentrations.

Materials And Methods: To further assess the role of sympathetic overactivity we compared the effects of different pharmacological interventions on smoking-induced changes of renal hemodynamics in occasional smokers. In a first series, placebo pretreatment plus smoking was compared to Prazosin pretreatment (3 mg) plus smoking. In a second study, placebo pretreatment plus smoking was compared to Atenolol pretreatment (50 mg) plus smoking.

Results: Basal blood pressure was significantly lower with Prazosin and Atenolol. On placebo, GFR and FF decreased significantly during smoking and RVR increased. With Prazosin pretreatment compared to placebo pretreatment no statistically significant differences for the changes of GFR, FF, RPF and RVR were seen. In contrast, with Atenolol pretreatment compared to placebo pretreatment, the smoking-induced changes in active renin, GFR and RVR were significantly smaller.

Conclusion: It is suggested that the acute renal hemodynamic effects of smoking are mediated, at least in part, via increased sympathetic activity operating mainly through beta-1 adrenergic mechanisms.

Citing Articles

Smoking and risk of incident end-stage kidney disease in general population: A Nationwide Population-based Cohort Study from Korea.

Choi H, Han K, Oh T, Kim C, Bae E, Ma S Sci Rep. 2019; 9(1):19511.

PMID: 31862942 PMC: 6925223. DOI: 10.1038/s41598-019-56113-7.


Helping Patients With ESRD and Earlier Stages of CKD to Quit Smoking.

Formanek P, Salisbury-Afshar E, Afshar M Am J Kidney Dis. 2018; 72(2):255-266.

PMID: 29661542 PMC: 6057817. DOI: 10.1053/j.ajkd.2018.01.057.


Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).

Staplin N, Haynes R, Herrington W, Reith C, Cass A, Fellstrom B Am J Kidney Dis. 2016; 68(3):371-80.

PMID: 27118687 PMC: 4996629. DOI: 10.1053/j.ajkd.2016.02.052.


Nicotine signaling and progression of chronic kidney disease in smokers.

Jain G, Jaimes E Biochem Pharmacol. 2013; 86(8):1215-23.

PMID: 23892062 PMC: 3838879. DOI: 10.1016/j.bcp.2013.07.014.


The effects of continuing and discontinuing smoking on the development of chronic kidney disease (CKD) in the healthy middle-aged working population in Japan.

Noborisaka Y, Ishizaki M, Yamada Y, Honda R, Yokoyama H, Miyao M Environ Health Prev Med. 2012; 18(1):24-32.

PMID: 22623223 PMC: 3541810. DOI: 10.1007/s12199-012-0285-7.